Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529175 | 0.86 | MAPT (0.57) | ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL6542710 | 0.80 | KDR (0.62) | KDRALDH1A1 | |
| SCHEMBL7996592 | 0.78 | KDR (0.45) | KDRALDH1A1SMN1; SMN2LMNAHDAC3 | |
| SCHEMBL1466583 | 0.76 | KDR (0.60) | KDRALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL11080584 | 0.75 | SCD (0.46) | SMN1; SMN2MAPTKDM4E | |
| SCHEMBL27089179 | 0.74 | KDM4E (0.56) | ALDH1A1MAPTKDM4E | |
| SCHEMBL11922254 | 0.74 | SCD (0.37) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16506482 | 0.74 | ALDH1A1 (0.43) | ALDH1A1LMNAKDM4E | |
| SCHEMBL26922126 | 0.73 | KDM4E (0.55) | ALDH1A1KDM4E | |
| SCHEMBL12296252 | 0.73 | SCD (0.44) | ALDH1A1SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071165-A1 | Aza- and polyazanthranyl amides and their use as medicaments | NOVARTIS AG (CH) | 2011-03-24 | — | — | US | claimed |
| US-20060287339-A1 | Aza- and polyazanthranyl amides and their use as medicaments | SEIDELMANN DIETER | 2006-12-21 | — | — | US | claimed |
| US-20040224968-A1 | Aza-and polyazanthranyl amides and their use as medicaments | NOVARTIS AG (CH) | 2004-11-11 | — | — | US | claimed |
| US-20110071165-A1 | Aza- and polyazanthranyl amides and their use as medicaments | NOVARTIS AG (CH) | 2011-03-24 | — | — | US | disclosed |
| US-20060287339-A1 | Aza- and polyazanthranyl amides and their use as medicaments | SEIDELMANN DIETER | 2006-12-21 | — | — | US | disclosed |
| US-20040224968-A1 | Aza-and polyazanthranyl amides and their use as medicaments | NOVARTIS AG (CH) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287339-A1 | Aza- and polyazanthranyl amides and their use as medicaments | VEGFA, AZI2, TPMT | KDR 8/4885ALDH1A1 764/4885SMN1; SMN2 4402/4885 |
| US-20040224968-A1 | Aza-and polyazanthranyl amides and their use as medicaments | AZI2, VEGFA, TPMT | KDR 19/4885ALDH1A1 530/4885SMN1; SMN2 4705/4885 |
| US-20110071165-A1 | Aza- and polyazanthranyl amides and their use as medicaments | VEGFA, AZI2, TPMT | KDR 8/4885ALDH1A1 764/4885SMN1; SMN2 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.